Blood cancer transplant study tests safer GVHD prevention

NCT ID NCT03246906

Terminated Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or post-transplant cyclophosphamide. The goal was to see which approach better prevents chronic GVHD and relapse. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclosporine, sirolimus, mycophenolate mofetil, cyclophosphamide
What this could lead to: If successful, this could identify a better drug combination to prevent graft-versus-host disease, improving survival and quality of life after stem cell transplant for blood cancers.
What could go wrong: This trial was terminated early, so results may be limited. The study is relatively small (150 participants) and focuses on a specific transplant setting, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia aggressive B-cell non-Hodgkin lymphoma B-cell chronic lymphocytic leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm chronic myelogenous leukemia, BCR-ABL1 positive diffuse large B-cell lymphoma hematologic disorder Hodgkins lymphoma Leukemia, Myelogenous, Chronic, BCR-ABL Positive mantle cell lymphoma myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma prolymphocytic leukemia Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA AGGRESSIVE NON-HODGKIN LYMPHOMA BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA HEMATOLOGIC AND LYMPHOCYTIC DISORDER MANTLE CELL LYMPHOMA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM PROLYMPHOCYTIC LEUKEMIA RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE RECURRENT HODGKIN LYMPHOMA RECURRENT PLASMA CELL MYELOMA RECURRENT SMALL LYMPHOCYTIC LYMPHOMA RECURRENT WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.